Fintel reports that on January 31, 2025, JMP Securities initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Market Outperform recommendation. Analyst Price Forecast Suggests 244.82% ...

JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...

JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Longer Term Trading Plans for ATXS. Buy ATXS near 7.19 target 9.02 stop loss @ 7.17 Details; The technical summary data tells us to buy ATXS near 7.19 with an upside target of 9.0 ...

LifeSprout, a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced it has filed for CE Mark registration for ...

BCT EXP, a global leader in digital transformation, user experiences, cross platform technologies and enterprise systems, today announced a formal partnership with OutSystems, a recognized pioneer in ...

According to a recent press release from Astria Therapeutics, the trial is anticipated to be initiated in the first quarter of 2025. Top-line results from ALPHA-ORBIT are expected in early 2027. The ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...